BHC

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2010, for Biovail Corporation (Note: The filing text identifies the registrant as Biovail Corporation, despite the request metadata referencing Bausch Health). Biovail is a specialty pharmaceutical company focused on developing and commercializing products for central nervous system (CNS) disorders. The company operates in a single segment: pharmaceutical products.

Key Financial Metrics

Debt and Liquidity: The company holds $350 million in 5.375% Senior Convertible Notes due 2014 and a $28.3 million obligation to Cambridge Laboratories. It maintains a $410 million senior secured revolving credit facility with no outstanding borrowings as of March 31, 2010. Working capital increased to $131.5 million.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 27% year-over-year, driven by incremental sales of Wellbutrin XL (following full U.S. rights acquisition), Xenazine, and increased demand for generic Tiazac and Cardizem CD due to competitor manufacturing issues.
• Profitability Decline: Net income swung from a $39.0 million profit in Q1 2009 to a $3.2 million loss in Q1 2010. This was primarily due to a $51.0 million charge for In-Process Research and Development (IPR&D) related to new acquisitions, a $17.8 million increase in amortization of intangible assets, and higher interest expenses.
• Expense Increases: Research and development expenses surged 360% to $66.9 million, almost entirely due to the $51.0 million IPR&D charge. Cost of goods sold rose 31% due to higher supply prices for Zovirax and lower-margin product mix.

Guidance, Outlook, and Risks

• Strategic Acquisitions: The company acquired rights to Staccato loxapine (for agitation in schizophrenia/bipolar) and AMPAKINE compounds (for respiratory depression). These were expensed immediately as IPR&D. Management plans to deploy a specialty U.S. sales force for these products, estimating costs of $10 million in late 2010 and $40–$70 million in 2011.
• Restructuring: The company sold its Dorado, Puerto Rico facility for $8.5 million. It expects to incur approximately $9.6 million in total employee termination costs for the closure of Puerto Rico facilities, recognizing these costs ratably over the service period.
• Dividend Policy: On May 5, 2010, the Board increased the quarterly dividend to $0.095 per share (from $0.090).
• Legal and Regulatory Risks:
  • Generic Competition: Significant exposure to generic entry for Ultram ER (100mg/200mg), Cardizem LA, and Glumetza (500mg). A Canadian court decision authorized a generic version of Glumetza 500mg in Canada.
  • Litigation: Ongoing antitrust class actions regarding Adalat CC and Wellbutrin XL. Patent infringement suits are active regarding Ultram ER, Cardizem CD, and Aplenzin.
  • Healthcare Reform: U.S. healthcare reform enacted in March 2010 may impact reimbursement rates and impose new fees, though the immediate financial impact in Q1 2010 was not material.

Investor Verification Checklist

• IPR&D Charges: Verify the strategic value and regulatory timelines for the $51 million spent on Staccato loxapine and AMPAKINE, given the immediate expense recognition.
• Generic Erosion: Monitor sales trends for Ultram ER and Cardizem LA as generic competitors gain market share.
• Litigation Outcomes: Track the status of the antitrust class actions and patent infringement suits, particularly the appeal regarding Ultram ER patent validity.
• Cash Burn vs. Generation: Assess whether operating cash flows ($44.8M) are sufficient to cover the planned $40–$70 million sales force build-out and ongoing restructuring costs without diluting shareholders or increasing debt.
• Convertible Notes: Review the terms of the $350 million Convertible Notes due 2014 and the company's intent to use net share settlement.